Compounding rules tighten around Pentadeca Arginate
2 independently tested samples across 2 companies, and what the results say about Pentadeca Arginate.
RegulationBPC-157 Arginate
Also known as: Stable BPC-157
Limited evidence
ClassArginate salt of BPC-157
Research statusPreclinical
Independent tests0
Studies indexed0
Overview
An arginate salt form of BPC-157 marketed for improved stability, with essentially no independent characterisation of that claim.
BPC-157 Arginate is classified as an arginate salt of bpc-157. Its current development status is: preclinical. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.
The Peptide Institute tracks BPC-157 Arginate because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Latest Coverage
Pentadeca Arginate enters a new trial phase, the questions it still has to answer
A close reading of the Pentadeca Arginate evidence, without the marketing layer.
NewsThe Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements